BRCA1 downregulates the kinase activity of Polo-like kinase 1 in response to replication stress

Cell Cycle

Volumn 12, Issue 14, 2013, Pages 2255-2265

  Zou, Jianqiu ^a   Rezvani, Khosrow ^a   Wang, Hongmin ^a   Lee, Kyung S ^b   Zhang, Dong ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

BRCA1; DNA damage; PLK1; Replication stress

Indexed keywords

AURORA A KINASE; BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE; POLO LIKE KINASE 1;

ARTICLE; DNA DAMAGE; DNA REPLICATION; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; STRESS;

EID: 84880421827     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25349     Document Type: Article

References (64)

1. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40:179-204; PMID:20965415; http://dx.doi.org/10. 1016/j.molcel.2010.09.019
2. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15:2177-96; PMID:11544175; http://dx.doi.org/10.1101/ gad.914401 (Pubitemid 32843830)
3. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 2009; 21:245-55; PMID:19230643; http://dx.doi.org/10.1016/j.ceb.2009.01.018
4. Medema RH, Macůrek L. Checkpoint control and cancer. Oncogene 2012; 31:2601-13; PMID:21963855; http://dx.doi.org/10.1038/onc.2011.451
5. van Vugt MA, Brás A, Medema RH. Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol Cell 2004; 15:799-811; PMID:15350223; http://dx.doi.org/10.1016/j.molcel.2004.07.015 (Pubitemid 39194909)
6. Seki A, Coppinger JA, Jang CY, Yates JR, Fang G. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 2008; 320:1655-8; PMID:18566290; http://dx.doi.org/10.1126/science. 1157425 (Pubitemid 351931258)
7. Macůrek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R, et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008; 455:119-23; PMID:18615013; http://dx.doi.org/10.1038/ nature07185
8. Mailand N, Falck J, Lukas C, Syljuâsen RG, Welcker M, Bartek J, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000; 288:1425-9; PMID:10827953; http://dx.doi.org/10.1126/science.288.5470.1425 (Pubitemid 30366329)
9. Lee J, Kumagai A, Dunphy WG. Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. Mol Biol Cell 2001; 12:551-63; PMID:11251070 (Pubitemid 33052011)
10. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2000; 2:672-6; PMID:10980711; http://dx.doi.org/10.1038/35023629
11. Krystyniak A, Garcia-Echeverria C, Prigent C, Ferrari S. Inhibition of Aurora A in response to DNA damage. Oncogene 2006; 25:338-48; PMID:16158051 (Pubitemid 43117619)
12. Tsvetkov L, Stern DF. Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage. Cell Cycle 2005; 4:166-71; PMID:15611664; http://dx.doi.org/10.4161/cc.4.1.1348 (Pubitemid 41038946)
13. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250:1684-9; PMID:2270482; http://dx.doi.org/10.1126/science.2270482 (Pubitemid 120031871)
14. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71; PMID:7545954; http://dx.doi.org/10.1126/ science.7545954 (Pubitemid 24345325)
15. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302:643-6; PMID:14576434; http://dx.doi.org/10.1126/science.1088759 (Pubitemid 37310920)
16. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007; 7:937-48; PMID:18034184; http://dx.doi.org/10.1038/nrc2054 (Pubitemid 350165853)
17. Shimizu Y, Mullins N, Blanchard Z, Elshamy WM. BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells. Oncotarget 2012; 3:299-313; PMID:22431556
18. O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 2010; 31:961-7; PMID:20400477; http://dx.doi.org/10.1093/carcin/ bgq069
19. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010; 11:138-48; PMID:20029420; http://dx.doi.org/10.1038/nrm2831
20. Martinez-Outschoorn UE, Balliet R, Lin Z, Whitaker- Menezes D, Birbe RC, Bombonati A, et al. BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies. Cell Cycle 2012; 11:4402-13; PMID:23172369; http://dx.doi.org/10.4161/cc.22776
21. Greenberg RA, Sobhian B, Pathania S, Cantor SB, Nakatani Y, Livingston DM. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev 2006; 20:34-46; PMID:16391231; http://dx.doi.org/10.1101/gad.1381306 (Pubitemid 43042666)
22. Wang B, Matsuoka S, Ballif BA, Zhang D, Smogorzewska A, Gygi SP, et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007; 316:1194-8; PMID:17525340; http://dx.doi.org/10.1126/ science. 1139476 (Pubitemid 46877482)
23. Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol 2009; 19:524-9; PMID:19268590; http://dx.doi.org/10.1016/j.cub.2009.02.018
24. Sy SM, Huen MS, Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci U S A 2009; 106:7155-60; PMID:19369211; http://dx.doi.org/10.1073/pnas.0811159106
25. Sobhian B, Shao G, Lilli DR, Culhane AC, Moreau LA, Xia B, et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007; 316:1198-202; PMID:17525341; http://dx.doi.org/10.1126/science.1139516 (Pubitemid 46877483)
26. Kim H, Chen J, Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 2007; 316:1202-5; PMID:17525342; http://dx.doi.org/10.1126/science.1139621 (Pubitemid 46877484)
27. Kim H, Huang J, Chen J. CCDC98 is a BRCA1- BRCT domain-binding protein involved in the DNA damage response. Nat Struct Mol Biol 2007; 14:710-5; PMID:17643122; http://dx.doi.org/10.1038/nsmb1277 (Pubitemid 47220062)
28. Liu Z, Wu J, Yu X. CCDC98 targets BRCA1 to DNA damage sites. Nat Struct Mol Biol 2007; 14:716-20; PMID:17643121; http://dx.doi.org/10.1038/nsmb1279 (Pubitemid 47220064)
29. Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 2002; 30:285-9; PMID:11836499; http://dx.doi.org/10.1038/ng837
30. Dever SM, White ER, Hartman MC, Valerie K. BRCA1-directed, enhanced and aberrant homologous recombination: mechanism and potential treatment strategies. Cell Cycle 2012; 11:687-94; PMID:22306997; http://dx.doi.org/10.4161/cc.11.4. 19212
31. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 1999; 4:511-8; PMID:10549283; http://dx.doi.org/10.1016/S1097-2765(00)80202-6 (Pubitemid 29531131)
32. You Z, Shi LZ, Zhu Q, Wu P, Zhang YW, Basilio A, et al. CtIP links DNA double-strand break sensing to resection. Mol Cell 2009; 36:954-69; PMID:20064462; http://dx.doi.org/10.1016/j.molcel.2009.12.002
33. Sartori AA, Lukas C, Coates J, Mistrik M, Fu S, Bartek J, et al. Human CtIP promotes DNA end resection. Nature 2007; 450:509-14; PMID:17965729; http://dx.doi.org/10.1038/nature06337 (Pubitemid 350190253)
34. Yun MH, Hiom K. CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. Nature 2009; 459:460-3; PMID:19357644; http://dx.doi.org/10.1038/nature07955
35. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999; 286:1162-6; PMID:10550055; http://dx.doi.org/10.1126/science.286. 5442.1162
36. Tibbetts RS, Cortez D, Brumbaugh KM, Scully R, Livingston D, Elledge SJ, et al. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev 2000; 14:2989-3002; PMID:11114888; http://dx.doi.org/10.1101/gad.851000
37. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010; 10:825-41; PMID:21102634; http://dx.doi.org/10.1038/nrc2964
38. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9:643-60; PMID:20671765; http://dx.doi.org/10.1038/nrd3184
39. Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 2009; 10:265-75; PMID:19305416; http://dx.doi.org/10.1038/nrm2653
40. Petronczki M, Lénárt P, Peters JM. Polo on the Risefrom Mitotic Entry to Cytokinesis with Plk1. Dev Cell 2008; 14:646-59; PMID:18477449; http://dx.doi.org/10.1016/j.devcel.2008.04.014 (Pubitemid 351622626)
41. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17:316-22; PMID:17291758; http://dx.doi.org/10.1016/j.cub.2006.12.037 (Pubitemid 46241881)
42. Cheung CH, Coumar MS, Hsieh HP, Chang JY. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 2009; 18:379-98; PMID:19335272; http://dx.doi.org/10.1517/13543780902806392
43. Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, Ongusaha PP, et al. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 2004; 279:19643-8; PMID:14990569; http://dx.doi.org/10.1074/jbc. M311780200 (Pubitemid 38623401)
44. Chan EH, Santamaria A, Silljé HH, Nigg EA. Plk1 regulates mitotic Aurora A function through betaTrCPdependent degradation of hBora. Chromosoma 2008; 117:457-69; PMID:18521620; http://dx.doi.org/10.1007/s00412-008-0165-5
45. Seki A, Coppinger JA, Du H, Jang CY, Yates JR 3rd, Fang G. Plk1- and beta-TrCP-dependent degradation of Bora controls mitotic progression. J Cell Biol 2008; 181:65-78; PMID:18378770; http://dx.doi.org/10.1083/jcb.200712027 (Pubitemid 351519765)
46. Leung CC, Glover JN. BRCT domains: easy as one, two, three. Cell Cycle 2011; 10:2461-70; PMID:21734457; http://dx.doi.org/10.4161/cc.10.15.16312
47. Lee YC, Liao PC, Liou YC, Hsiao M, Huang CY, Lu PJ. Glycogen synthase kinase 3 β activity is required for hBora/Aurora A-mediated mitotic entry. Cell Cycle 2013; 12:953-60; PMID:23442801; http://dx.doi.org/10.4161/cc.23945
48. Qian YW, Erikson E, Maller JL. Mitotic effects of a constitutively active mutant of the Xenopus pololike kinase Plx1. Mol Cell Biol 1999; 19:8625-32; PMID:10567586 (Pubitemid 30414055)
49. Jang YJ, Ma S, Terada Y, Erikson RL. Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian polo-like kinase. J Biol Chem 2002; 277:44115-20; PMID:12207013; http://dx.doi.org/10.1074/jbc.M202172200 (Pubitemid 36157840)
50. Kang YH, Park JE, Yu LR, Soung NK, Yun SM, Bang JK, et al. Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation. Mol Cell 2006; 24:409-22; PMID:17081991; http://dx.doi.org/10.1016/j.molcel.2006.10.016 (Pubitemid 44754942)
51. Park JE, Li L, Park J, Knecht R, Strebhardt K, Yuspa SH, et al. Direct quantification of polo-like kinase 1 activity in cells and tissues using a highly sensitive and specific ELISA assay. Proc Natl Acad Sci U S A 2009; 106:1725-30; PMID:19181852; http://dx.doi.org/10.1073/pnas.0812135106
52. van Vugt MA, Smits VA, Klompmaker R, Medema RH. Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM- or ATR-dependent fashion. J Biol Chem 2001; 276:41656-60; PMID:11514540; http://dx.doi.org/10.1074/jbc.M101831200
53. Shang ZF, Yu L, Li B, Tu WZ, Wang Y, Liu XD, et al. 4E-BP1 participates in maintaining spindle integrity and genomic stability via interacting with PLK1. Cell Cycle 2012; 11:3463-71; PMID:22918237; http://dx.doi.org/10.4161/cc. 21770
54. Lowery DM, Clauser KR, Hjerrild M, Lim D, Alexander J, Kishi K, et al. Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J 2007; 26:2262-73; PMID:17446864; http://dx.doi.org/10. 1038/sj.emboj.7601683 (Pubitemid 46685865)
55. Archambault V, Carmena M. Polo-like kinase-activating kinases: Aurora A, Aurora B and what else? Cell Cycle 2012; 11:1490-5; PMID:22433949; http://dx.doi.org/10.4161/cc.19724
56. van Vugt MA, Gardino AK, Linding R, Ostheimer GJ, Reinhardt HC, Ong SE, et al. A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpoint. PLoS Biol 2010; 8:e1000287; PMID:20126263; http://dx.doi.org/10.1371/journal. pbio.1000287
57. van Vugt MA, Yaffe MB. Cell cycle re-entry mechanisms after DNA damage checkpoints: giving it some gas to shut off the breaks! Cell Cycle 2010; 9:2097-101; PMID:20505366; http://dx.doi.org/10.4161/cc.9.11.11840
58. Yoo HY, Kumagai A, Shevchenko A, Shevchenko A, Dunphy WG. Adaptation of a DNA replication checkpoint response depends upon inactivation of Claspin by the Polo-like kinase. Cell 2004; 117:575-88; PMID:15163406; http://dx.doi.org/10. 1016/S0092-8674(04)00417-9 (Pubitemid 38692524)
59. Menzel T, Nähse-Kumpf V, Kousholt AN, Klein DK, Lund-Andersen C, Lees M, et al. A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance. EMBO Rep 2011; 12:705-12; PMID:21637299; http://dx.doi.org/10.1038/embor.2011.99
60. Cotta-Ramusino C, McDonald ER 3rd, Hurov K, Sowa ME, Harper JW, Elledge SJ. A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 interacting protein required for ATR signaling. Science 2011; 332:1313-7; PMID:21659603; http://dx.doi.org/10.1126/science.1203430
61. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, et al. DNA damage response as a candidate anticancer barrier in early human tumorigenesis. Nature 2005; 434:864-70; PMID:15829956; http://dx.doi.org/10. 1038/nature03482 (Pubitemid 40558993)
62. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-13; PMID:15829965; http://dx.doi.org/10.1038/nature03485 (Pubitemid 40559004)
63. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6:321-30; PMID:16557283; http://dx.doi.org/10.1038/nrc1841
64. Wei L, Lan L, Hong Z, Yasui A, Ishioka C, Chiba N. Rapid recruitment of BRCA1 to DNA double-strand breaks is dependent on its association with Ku80. Mol Cell Biol 2008; 28:7380-93; PMID:18936166; http://dx.doi.org/10.1128/MCB.01075- 08